Clinical Trials Browser

Lymphoma, Non-Hodgkin × tenalisib × Clear all

NCT03711578 2021-08-12

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Phase 2 Completed

20 enrolled 10 charts

Lymphoma, Non-Hodgkin

NCT02017613 2016-06-24

PI3K

Phase 1 Completed

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous